Key result
SGLT2 inhibitors in acute Takotsubo syndrome linked to reduced myocardial edema and improved LVEF.
Why the study?
SGLT2 inhibitors are approved for heart failure, but few data are available regarding their safety, tolerability, and effects on myocardial recovery and inflammation in acute takotsubo syndrome.
Does SGLT2 inhibitor therapy improve myocardial edema burden and LVEF in patients with acute Takotsubo syndrome?
Cohort (n=66)
Does SGLT2 inhibitor therapy improve myocardial edema burden and LVEF in patients with acute Takotsubo syndrome?
Early administration of SGLT2 inhibitors in acute Takotsubo syndrome is safe and associated with reduced myocardial edema and improved left ventricular ejection fraction within the first week.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for early SGLT2 inhibitor use in Takotsubo syndrome; prospective randomized trials needed before clinical adoption.
BACKGROUND SGLT2 inhibitors are approved for heart failure treatment, however, few data are available in patients with takotsubo syndrome (TTS). We aim to evaluate the safety, tolerability and effects of SGLT2 inhibitors therapy on myocardial recovery and inflammation in acute TTS. METHODS We compared n = 22 SGLT2 inhibitors treated TTS patients (Dapagliflozin n = 13, Empagliflozin n = 9) with n = 44 1:2 propensity-score matched untreated. Treated patients were mostly consecutively enrolled after implementation of 2023 ESC heart failure guidelines. All underwent cardiac magnetic resonance (CMR) imaging with T2 mapping within 7 days of hospital admission. SGLT2 inhibitors were first administered within 6 h of admission. The primary endpoint was myocardial edema burden as measured by CMR septal T2 mapping. Secondary endpoints were global T2 mapping and left ventricular ejection fraction (LVEF). RESULTS After matching, all variables associated with recovery of LV function and edema were proportionally distributed between groups, including age, sex, echocardiographic LVEF on admission, comorbidities and time from admission to CMR imaging. At CMR imaging, treated patients showed similar basal (p = 0.956) while significantly lower septal (56 ms vs 59 ms, p = 0.034) and global (55 ms vs 57 ms, p = 0.049) T2 mapping values, and higher LVEF (55% vs 50%, p = 0.048) compared to controls. We observed no drug-related adverse effects during hospitalization, discontinuation rate at follow-up was 4.5%. CONCLUSIONS In acute TTS, SGLT2 inhibitors treatment was safe and well tolerated. CMR within one week of hospitalization showed lower myocardial edema burden and higher LVEF in SGLT2 inhibitors treated patients, suggesting quicker recovery of myocardial function.
No takes yet. Share an insight, caveat, or question.
Arcari et al. (2026) conducted a cohort in Acute Takotsubo syndrome (n=66). SGLT2 inhibitors (Dapagliflozin or Empagliflozin) vs. Untreated controls was evaluated on Myocardial edema burden as measured by CMR septal T2 mapping (p=0.034). SGLT2 inhibitors in acute Takotsubo syndrome reduced septal T2 mapping and improved LVEF compared to untreated controls.
Synapse has enriched 10 related papers. Consider them for comparative context: